Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/lap.2015.9992 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The 25th Anniversary of : Marking This Significant Milestone.
Curr Issues Mol Biol
December 2024
Department of Pathology and Biomedical Science, University of Otago, Christchurch 8140, New Zealand.
(https://www [...
View Article and Find Full Text PDFHistory and Development of the Society of Heart Failure Specialists (On the 25th Anniversary of the Society).
Kardiologiia
November 2024
Sechenov First Moscow State Medical University, Department and Clinic of Hospital Therapy #1 of the Sklifosovsky Institute of Clinical Medicine, Moscow.
During the 25 years of the existence of the Russian Society of Experts in Heart Failure, it has become the most numerous and authoritative medical association. The Society has representative offices in 52 regions of Russia, and its active members amount to more than 4,000 various specialists. More than 200 Schools, regional conferences, and annual Congresses have been held annually.
View Article and Find Full Text PDFSpecial Issue Celebrating the 25 Anniversary of the Institute of Neuroscience, CAS.
Neurosci Bull
November 2024
Department of Neurology of Second Affiliated Hospital and School of Brain Science and Brain Medicine, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Cover Story for "CMAQ 25 Anniversary".
EM (Pittsburgh Pa)
January 2024
Research Physical Scientists with the U.S. Environmental Protection Agency's Office of Research and Development. Both are long-time members of the development team for the CMAQ modeling system. Sarwar is also a member of EM's Editorial Advisory Committee (EAC).
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer.
Nat Rev Drug Discov
December 2024
Laboratory of Molecular Immunology, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA.
The first anti-tumour necrosis factor (TNF) monoclonal antibody, infliximab (Remicade), celebrated its 25th anniversary of FDA approval in 2023. Inhibitors of TNF have since proved clinically efficacious at reducing inflammation associated with several autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease. The success of TNF inhibitors raised unrealistic expectations for targeting other members of the TNF superfamily (TNFSF) of ligands and their receptors, with difficulties in part related to their more limited, variable expression and potential redundancy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!